Literature DB >> 28197932

Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles.

Thi Ngoc Lan Vuong1,2, M T Ho3,4, T Q Ha3, M Brehm Jensen5, C Yding Andersen5, P Humaidan6,7.   

Abstract

PURPOSE: A recent dose-finding study showed no significant differences in number of mature oocytes, embryos and top-quality embryos when triptorelin doses of 0.2, 0.3 or 0.4 mg were used to trigger final oocyte maturation in oocyte donors co-treated with a gonadotropin-releasing hormone (GnRH) antagonist. This analysis investigated whether triptorelin dosing for triggering final oocyte maturation in oocyte donors induced differences in follicular fluid (FF) hormone levels and granulosa cell gene expression.
METHODS: This single-centre, randomised, parallel, investigator-blinded trial was conducted in oocyte donors undergoing a single stimulation cycle at IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam, from August 2014 to March 2015. A total of 165 women aged 18-35 years with body mass index <28 kg/m2, anti-Müllerian hormone >1.25 ng/mL, and antral follicle count ≥6 were randomised to three different triptorelin doses for trigger. The main outcome was concentration of steroid hormones in FF collected from the first punctured follicle on each side. Moreover, luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD) and inhibin-Ba (INHB-A) gene expression in cumulus and mural granulosa cells were investigated in a subset of women from each group.
RESULTS: Progesterone and oestradiol levels in FF did not differ significantly by trigger doses; findings were similar for 3βHSD, LHR and INHB-A gene expression in both cumulus and mural granulosa cells.
CONCLUSIONS: In women co-treated with a GnRH antagonist, no significant differences in FF steroid levels and granulosa cell gene expression were seen when different triptorelin doses were used to trigger final oocyte maturation.

Entities:  

Keywords:  Follicular fluid; Gonadotropin-releasing hormone agonist trigger; In vitro fertilisation; LHR gene expression; Triptorelin

Mesh:

Substances:

Year:  2017        PMID: 28197932      PMCID: PMC5401703          DOI: 10.1007/s10815-017-0891-9

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  21 in total

1.  First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462).

Authors:  J Itskovitz-Eldor; S Kol; B Mannaerts; H Coelingh Bennink
Journal:  Hum Reprod       Date:  1998-02       Impact factor: 6.918

Review 2.  GnRH agonist for triggering of final oocyte maturation: time for a change of practice?

Authors:  P Humaidan; S Kol; E G Papanikolaou
Journal:  Hum Reprod Update       Date:  2011-03-30       Impact factor: 15.610

3.  Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.

Authors:  C Albano; J Smitz; M Camus; H Riethmüller-Winzen; A Van Steirteghem; P Devroey
Journal:  Fertil Steril       Date:  1997-05       Impact factor: 7.329

4.  Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.

Authors:  G Borm; B Mannaerts
Journal:  Hum Reprod       Date:  2000-07       Impact factor: 6.918

Review 5.  Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches.

Authors:  Peter Humaidan; Lawrence Engmann; Claudio Benadiva
Journal:  Fertil Steril       Date:  2015-02-11       Impact factor: 7.329

6.  Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.

Authors:  Vuong Thi Ngoc Lan; Nguyen Khanh Linh; Ho Manh Tuong; P C Wong; Colin M Howles
Journal:  Reprod Biomed Online       Date:  2013-07-23       Impact factor: 3.828

7.  Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.

Authors:  P Humaidan; I Van Vaerenbergh; C Bourgain; B Alsbjerg; C Blockeel; F Schuit; L Van Lommel; P Devroey; H Fatemi
Journal:  Hum Reprod       Date:  2012-08-28       Impact factor: 6.918

8.  Induction of luteinized unruptured follicles in the rat after injection of luteinizing hormone early in pro-oestrus.

Authors:  J A Mattheij; H J Swarts
Journal:  Eur J Endocrinol       Date:  1995-01       Impact factor: 6.664

9.  Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.

Authors:  Thi Ngoc Lan Vuong; Manh Tuong Ho; Tan Duc Ha; Huy Tuan Phung; Gia Bao Huynh; Peter Humaidan
Journal:  Fertil Steril       Date:  2015-10-31       Impact factor: 7.329

10.  GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.

Authors:  P Humaidan; N P Polyzos; B Alsbjerg; K Erb; A L Mikkelsen; H O Elbaek; E G Papanikolaou; C Y Andersen
Journal:  Hum Reprod       Date:  2013-06-09       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.